Addition of Metformin to Liraglutide, A GLP-1 Receptor Agonist, Improves Glycemic Control in Patients with Type 2 Diabetes Mellitus
Journal Title: Journal of Diabetes and Obesity - Year 2016, Vol 4, Issue 1
Abstract
Background: The maximum permissible dose of liraglutide, a GLP-1 receptor agonist, under the Japanese Heath Insurance system is 0.9 mg/day. We determined the effects of adding metformin to liraglutide therapy in Japanese patients with type 2 diabetes. Material and Methods: This observational retrospective study included 47 patients with type 2 diabetes who were treated with liraglutide alone or in combination with sulfonylureas. Metformin was added at a dose ranging from 250 to 500 mg/day based on inadequate glycemic control. Liraglutide and metformin doses were converted from mg/day to mg/kg body weight/day before analysis of the correlation between the dose and changes in glycated hemoglobin (HbA1c) and body mass index (BMI). Results: Both HbA1c and BMI decreased significantly after 24 weeks of the combination treatment. Mild gastrointestinal adverse events were reported by 21% of the patients. Only the dose of metformin, but not that of liraglutide, expressed in mg/kg body weight was correlated significantly with decrease in HbA1c and BMI. Conclusions: The addition of metformin to the maximum permissible dose of liraglutide helps secure glycemic control and reduce BMI in Japanese patients with type 2 diabetes who exhibit inadequate response to liraglutide.
Authors and Affiliations
Masao Toyoda
Keywords
Related Articles
- EP ID EP417851
- DOI 10.15436/2376-0494.17.1300
- Views 116
- Downloads 0
A Calorie is Still a Calorie, According to Rigorous New Evidence
Chronic degenerative “diseases of civilization” are the top challenges of all health systems globally. Among them, obesity is the most pernicious because it a) has survived several meritorious lifestyle initiatives undet...
Vagal Nerve Block for Improvements in Glycemic Control in Obese Patients with Type 2 Diabetes Mellitus: Three-Year Results of the VBLOC DM2 Study
Background: The VBLOC DM2 study demonstrated that intermittent electrical vagal blocking (vBloc therapy) was safe among subjects with obesity and type 2 diabetes mellitus (DM2) and led to clinically meaningful improvemen...
Comparative Efficiency of Sulfonylurea and/or Dipeptidyl Peptidase-4 inhibitor in Basal-Supported Oral Therapy in Japanese Patients with Type 2 Diabetes (JDDM39)
Basal-supported Oral Therapy BOT comprising treatment with oral antidiabetic drugs and once-daily injections of a long-acting insulin analog is a convenient regimen However it sometimes fails to achieve satisfactor...
The Relationship between Obesity and Diabetes
Diabetes mellitus (DM) is a lifelong condition that can transform carbohydrate, protein and fat metabolism. The cause of which is the lack of the hormone insulin as a result of either the ongoing or striking failure of t...
Association between Epicardial Fat, Metabolic Syndrome and Obesity
Epicardial fat is true visceral fat deposited around sub epicardial coronary vessels; it has been implicated in the development of coronary atherosclerosis. Epicardial fat has been also associated with insulin resistance...